Allianz Asset Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$26.7M Buy
48,445
+10,697
+28% +$6.02M 0.02% 616
2026
Q1
$22.4M Buy
37,748
+14,244
+61% +$7.09M 0.02% 583
2025
Q4
$11.5M Sell
23,504
-21,568
-48% -$10M 0.01% 802
2025
Q3
$18.9M Sell
45,072
-19,018
-30% -$6.4M 0.02% 610
2025
Q2
$18.4M Sell
64,090
-3,486
-5% -$1.04M 0.02% 599
2025
Q1
$20.8M Buy
67,576
+33,254
+97% +$11.4M 0.03% 553
2024
Q4
$12.1M Sell
34,322
-15,877
-32% -$5.84M 0.02% 693
2024
Q3
$18M Buy
50,199
+5,231
+12% +$1.77M 0.03% 569
2024
Q2
$14.3M Buy
44,968
+11,503
+34% +$3.04M 0.02% 603
2024
Q1
$7.69M Buy
33,465
+3,198
+11% +$722K 0.01% 727
2023
Q4
$6.66M Buy
30,267
+2,409
+9% +$555K 0.01% 820
2023
Q3
$6.29M Sell
27,858
-12,900
-32% -$2.97M 0.01% 900
2023
Q2
$9M Sell
40,758
-200,626
-83% -$44.4M 0.02% 678
2023
Q1
$54.1M Buy
241,384
+50,888
+27% +$12.5M 0.1% 209
2022
Q4
$53M Sell
190,496
-25,060
-12% -$6.33M 0.1% 198
2022
Q3
$45.1M Buy
215,556
+12,425
+6% +$2.78M 0.09% 222
2022
Q2
$47.9M Buy
203,131
+27,922
+16% +$5.68M 0.05% 404
2022
Q1
$31.4M Sell
175,209
-90,029
-34% -$17.2M 0.02% 599
2021
Q4
$57.3M Buy
265,238
+93,847
+55% +$18.4M 0.04% 444
2021
Q3
$31.6M Buy
171,391
+66,474
+63% +$13.1M 0.02% 572
2021
Q2
$18.8M Buy
104,917
+56,599
+117% +$10.8M 0.02% 665
2021
Q1
$8.08M Buy
48,318
+26,830
+125% +$4.47M 0.01% 899
2020
Q4
$3.26M Sell
21,488
-2,867
-12% -$376K ﹤0.01% 1174
2020
Q3
$2.46M Sell
24,355
-21,232
-47% -$2.33M ﹤0.01% 1187
2020
Q2
$5.52M Sell
45,587
-3,893
-8% -$438K 0.01% 1165
2020
Q1
$4.69M Buy
49,480
+23,316
+89% +$2.22M 0.01% 1189
2019
Q4
$2.31M Buy
26,164
+5,235
+25% +$461K ﹤0.01% 1805
2019
Q3
$1.67M Sell
20,929
-73,552
-78% -$5.92M ﹤0.01% 1907
2019
Q2
$7.38M Sell
94,481
-11,087
-11% -$1.04M 0.01% 1324
2019
Q1
$12.4M Sell
105,568
-2,437
-2% -$284K 0.01% 1024
2018
Q4
$11.8M Buy
108,005
+6,657
+7% +$772K 0.01% 1036
2018
Q3
$13M Buy
101,348
+63,664
+169% +$7.87M 0.01% 1137
2018
Q2
$4.26M Sell
37,684
-3,049
-7% -$335K ﹤0.01% 1597
2018
Q1
$4.58M Buy
40,733
+420
+1% +$53.4K ﹤0.01% 1572
2017
Q4
$5.96M Sell
40,313
-43,751
-52% -$5.56M ﹤0.01% 1549
2017
Q3
$9.85M Sell
84,064
-3,357
-4% -$429K 0.01% 1333
2017
Q2
$11.4M Sell
87,421
-6,816
-7% -$850K 0.01% 1261
2017
Q1
$12.8M Sell
94,237
-2,662
-3% -$403K 0.01% 1229
2016
Q4
$13.9M Sell
96,899
-9,621
-9% -$1.23M 0.01% 1207
2016
Q3
$12.4M Sell
106,520
-33,775
-24% -$4.06M 0.01% 1221
2016
Q2
$14.9M Sell
140,295
-36,326
-21% -$4.05M 0.02% 1057
2016
Q1
$19.7M Sell
176,621
-5,767
-3% -$730K 0.02% 792
2015
Q4
$28.7M Sell
182,388
-42,518
-19% -$6.19M 0.03% 589
2015
Q3
$29.5M Sell
224,906
-185
-0.1% -$29.7K 0.04% 564
2015
Q2
$39.2M Sell
225,091
-60,243
-21% -$10.8M 0.04% 522
2015
Q1
$49.2M Sell
285,334
-138,215
-33% -$21.1M 0.06% 370
2014
Q4
$54.8M Sell
423,549
-100,215
-19% -$12.9M 0.06% 358
2014
Q3
$67.4M Buy
523,764
+43,219
+9% +$4.46M 0.08% 290
2014
Q2
$42.5M Buy
480,545
+161,311
+51% +$15.5M 0.05% 373
2014
Q1
$30M Buy
319,234
+37,049
+13% +$3.79M 0.04% 453
2013
Q4
$31.9M Buy
282,185
+216,655
+331% +$19.5M 0.04% 437
2013
Q3
$5.17M Sell
65,530
-17,300
-21% -$1.26M 0.01% 911
2013
Q2
$5.45M Buy
+82,830
New +$5.34M 0.01% 864

Other funds holding UTHR

Allianz Asset Management's UTHR Position: Q2 2026 in Review

Allianz Asset Management increased its United Therapeutics (UTHR) stake by 28% in Q2 2026, buying an estimated $6.02M and bringing the position to 48,445 shares worth $26.7M. The position accounts for 0.02% of the portfolio, ranked #616.

Allianz Asset Management first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $67.4M in Q3 2014. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Allianz Asset Management held 48,445 shares of United Therapeutics worth $26.7M as of Q2 2026.
  • Allianz Asset Management bought 10,697 United Therapeutics shares in Q2 2026, an estimated $6.02M.
  • United Therapeutics made up 0.02% of Allianz Asset Management's portfolio in Q2 2026, its #616 holding.
  • Allianz Asset Management first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Allianz Asset Management's United Therapeutics position peaked at $67.4M in Q3 2014.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.